Oral diseases · 2026
AQP1 Corrects Acinar Cells' Secretion Deficits in Sjögren's Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perez Paola, Warner Blake M, Ji Youngmi, Afione Sandra, Pranzatelli Thomas J F, Beach Margaret E, Khavandgar Zohreh, Grisius Margie, Pelayo Eileen, Martin Daniel, NIDCD/NIDCR Genomics and Computational Biology Core, Baer Alan N, Chiorini John A
Аннотация
INTRODUCTION: Sjögren's disease (SjD) is a systemic autoimmune disease characterized by dry mouth, dry eyes, and profound fatigue. Preclinical studies suggest that AQP1 gene expression in salivary glands corrects salivary hypofunction in preclinical and clinical studies of radiation-induced xerostomia and improves salivary and lacrimal function in SjD mouse models.
SUBJECTS AND METHODS: To evaluate its therapeutic potential, we tested AQP1 gene therapy using labial salivary gland (LSG) biopsies from patients with SjD, non-SjD, and healthy volunteer glands (HV).
RESULTS: Ex vivo cultures of LSG lobules were viable, responsive to stimulation, and transducible with an AAV2 vector encoding AQP1. AQP1 expression increased fluid secretion in most samples, with recovery reaching up to 80% of healthy volunteer levels. Baseline transcriptomic analysis identifies 94 genes that correlated with treatment response, with inflammatory and epithelial signature correlating with success and fibrotic signatures with non-response. Histological evaluation confirmed greater fibrosis in non-responding samples. Thus, treatment effects were functionally significant but transcriptionally minimal indicating targeted therapeutic action without altering homeostatic transcription.
CONCLUSION: These findings demonstrate that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.
SUBJECTS AND METHODS: To evaluate its therapeutic potential, we tested AQP1 gene therapy using labial salivary gland (LSG) biopsies from patients with SjD, non-SjD, and healthy volunteer glands (HV).
RESULTS: Ex vivo cultures of LSG lobules were viable, responsive to stimulation, and transducible with an AAV2 vector encoding AQP1. AQP1 expression increased fluid secretion in most samples, with recovery reaching up to 80% of healthy volunteer levels. Baseline transcriptomic analysis identifies 94 genes that correlated with treatment response, with inflammatory and epithelial signature correlating with success and fibrotic signatures with non-response. Histological evaluation confirmed greater fibrosis in non-responding samples. Thus, treatment effects were functionally significant but transcriptionally minimal indicating targeted therapeutic action without altering homeostatic transcription.
CONCLUSION: These findings demonstrate that AAV2-AQP1 expression enhances fluid secretion in human LSGs and highlight fibrosis-associated loss of glandular parenchyma as a major barrier to therapeutic efficacy.